Buckeyes fwiw I don't see Ori or anyone else "banking up" Hepalink to take out RVX either.  I have always thought that given Hepalink's relatively small size as a pharma and the deal they have with RVX that they have always been in this to make a windfall profit from selling their RVX holdings, keeping their manufacturing and distribution rights in China etc for a bigger long term revenue stream and perhaps, once a BP buys RVX, having an inside track on manufacturing (their real expertise) in other parts of the world where they already have facilities for another future revenue stream. 

My only caveat to this would be Hepalink taking out RVX with a real BP partner with whom they already have a relationship. Novartis comes to mind in this regard.